Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
The Unique Combination of Multi-dimensional Genomics & AI in Cancer Care
Detection
Early cancer detection by screening for tumor DNA in the blood (ctDNA).
Profiling
Next-generation sequencing (NGS) tumor profiling for precision therapies.
Monitoring
Personalized ctDNA monitoring for recurrence risk and treatment responses.
Innovation
Discovery of multi-omics targets for new drug insights and novel therapies development.
News & Updates
Get the latest news and updates of our company and medical field.
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Next-generation AI-Powered Multi-Cancer Early Detection Takes Center Stage at Gene Solutions Hong Kong Symposium During MMMC 2026
The conversation around cancer screening is changing. For decades, cancer screening has largely focused on detecting individual cancers through separate tests. With advances in Artificial Intelligence (AI) and multi-omics technologies, new possibilities are emerging for identifying multiple cancers from a single
Introducing SPOT-MAS in Brazil: Advancing Access to Multi-Cancer Screening Through Genomic Innovation in Latin America.
São Paulo, June 25, 2026 — Gene Solutions Brazil and Bioma Genetics announced the introduction of SPOT-MAS in Brazil during an exclusive scientific event held in São Paulo, marking an important step in expanding access to
Gene Solutions Contributes Latest Prenatal Genomics Findings and Women’s Health Research at ISPD 2026
Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster
SPOT-MAS 10 Real-World Data Highlighted by ASCO Ahead of ASCO Breakthrough 2026
Gene Solutions’ SPOT-MAS 10 real-world data was highlighted by ASCO ahead of ASCO Breakthrough 2026, recognizing evidence from 84,145 asymptomatic individuals across 6 Asian countries. Dr. Dang Nguyen also received
ASCO 2026 RECAP | GENE SOLUTIONS PRESENT TWO CLINICAL STUDIES ADVANCING ctDNA APPLICATIONS IN CANCER CARE
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, Gene Solutions, in collaboration with the Medical Genetics Institute (MGI), proudly presented two landmark scientific abstracts.
Best of K‑CONNECT Summit 2026: Translating Multi-omics and AI Into Real-World Precision Oncology
At the K-CONNECT Summit 2026 in Da Nang, more than 250 international experts attended onsite, while over 1,000 participants joined online to explore how multi-omics, liquid biopsy, and Artificial Intelligence
Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test SINGAPORE, 28 May 2026 — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
TAIPEI, May 22, 2026 — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking
Single-Gene Disorders. Lifelong Impact. Early Screening Matters.
8 May marks World Thalassemia Day — a global moment to honor families living with thalassemia and raise awareness of inherited blood disorders. In 2026, the global campaign theme, “Hidden No More:
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Next-generation AI-Powered Multi-Cancer Early Detection Takes Center Stage at Gene Solutions Hong Kong Symposium During MMMC 2026
The conversation around cancer screening is changing. For decades, cancer screening has largely focused on detecting individual cancers through separate tests. With advances in Artificial Intelligence (AI) and multi-omics technologies, new possibilities are emerging for identifying multiple cancers from a single
Introducing SPOT-MAS in Brazil: Advancing Access to Multi-Cancer Screening Through Genomic Innovation in Latin America.
São Paulo, June 25, 2026 — Gene Solutions Brazil and Bioma Genetics announced the introduction of SPOT-MAS in Brazil during an exclusive scientific event held in São Paulo, marking an important step in expanding access to
Gene Solutions Contributes Latest Prenatal Genomics Findings and Women’s Health Research at ISPD 2026
Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster
SPOT-MAS 10 Real-World Data Highlighted by ASCO Ahead of ASCO Breakthrough 2026
Gene Solutions’ SPOT-MAS 10 real-world data was highlighted by ASCO ahead of ASCO Breakthrough 2026, recognizing evidence from 84,145 asymptomatic individuals across 6 Asian countries. Dr. Dang Nguyen also received
ASCO 2026 RECAP | GENE SOLUTIONS PRESENT TWO CLINICAL STUDIES ADVANCING ctDNA APPLICATIONS IN CANCER CARE
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, Gene Solutions, in collaboration with the Medical Genetics Institute (MGI), proudly presented two landmark scientific abstracts.
Best of K‑CONNECT Summit 2026: Translating Multi-omics and AI Into Real-World Precision Oncology
At the K-CONNECT Summit 2026 in Da Nang, more than 250 international experts attended onsite, while over 1,000 participants joined online to explore how multi-omics, liquid biopsy, and Artificial Intelligence
Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test SINGAPORE, 28 May 2026 — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
TAIPEI, May 22, 2026 — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking
Single-Gene Disorders. Lifelong Impact. Early Screening Matters.
8 May marks World Thalassemia Day — a global moment to honor families living with thalassemia and raise awareness of inherited blood disorders. In 2026, the global campaign theme, “Hidden No More:
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test SINGAPORE, 28 May 2026 — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
TAIPEI, May 22, 2026 — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking
Single-Gene Disorders. Lifelong Impact. Early Screening Matters.
8 May marks World Thalassemia Day — a global moment to honor families living with thalassemia and raise awareness of inherited blood disorders. In 2026, the global campaign theme, “Hidden No More:
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Next-generation AI-Powered Multi-Cancer Early Detection Takes Center Stage at Gene Solutions Hong Kong Symposium During MMMC 2026
The conversation around cancer screening is changing. For decades, cancer screening has largely focused on detecting individual cancers through separate tests. With advances in Artificial Intelligence (AI) and multi-omics technologies, new possibilities are emerging for identifying multiple cancers from a single
Introducing SPOT-MAS in Brazil: Advancing Access to Multi-Cancer Screening Through Genomic Innovation in Latin America.
São Paulo, June 25, 2026 — Gene Solutions Brazil and Bioma Genetics announced the introduction of SPOT-MAS in Brazil during an exclusive scientific event held in São Paulo, marking an important step in expanding access to
Gene Solutions Contributes Latest Prenatal Genomics Findings and Women’s Health Research at ISPD 2026
Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster
SPOT-MAS 10 Real-World Data Highlighted by ASCO Ahead of ASCO Breakthrough 2026
Gene Solutions’ SPOT-MAS 10 real-world data was highlighted by ASCO ahead of ASCO Breakthrough 2026, recognizing evidence from 84,145 asymptomatic individuals across 6 Asian countries. Dr. Dang Nguyen also received
ASCO 2026 RECAP | GENE SOLUTIONS PRESENT TWO CLINICAL STUDIES ADVANCING ctDNA APPLICATIONS IN CANCER CARE
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, Gene Solutions, in collaboration with the Medical Genetics Institute (MGI), proudly presented two landmark scientific abstracts.
Best of K‑CONNECT Summit 2026: Translating Multi-omics and AI Into Real-World Precision Oncology
At the K-CONNECT Summit 2026 in Da Nang, more than 250 international experts attended onsite, while over 1,000 participants joined online to explore how multi-omics, liquid biopsy, and Artificial Intelligence
Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test SINGAPORE, 28 May 2026 — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
TAIPEI, May 22, 2026 — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking
Single-Gene Disorders. Lifelong Impact. Early Screening Matters.
8 May marks World Thalassemia Day — a global moment to honor families living with thalassemia and raise awareness of inherited blood disorders. In 2026, the global campaign theme, “Hidden No More:
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
Next-generation AI-Powered Multi-Cancer Early Detection Takes Center Stage at Gene Solutions Hong Kong Symposium During MMMC 2026
The conversation around cancer screening is changing. For decades, cancer screening has largely focused on detecting individual cancers through separate tests. With advances in Artificial Intelligence (AI) and multi-omics technologies, new possibilities are emerging for identifying multiple cancers from a single
Introducing SPOT-MAS in Brazil: Advancing Access to Multi-Cancer Screening Through Genomic Innovation in Latin America.
São Paulo, June 25, 2026 — Gene Solutions Brazil and Bioma Genetics announced the introduction of SPOT-MAS in Brazil during an exclusive scientific event held in São Paulo, marking an important step in expanding access to
Gene Solutions Contributes Latest Prenatal Genomics Findings and Women’s Health Research at ISPD 2026
Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster
SPOT-MAS 10 Real-World Data Highlighted by ASCO Ahead of ASCO Breakthrough 2026
Gene Solutions’ SPOT-MAS 10 real-world data was highlighted by ASCO ahead of ASCO Breakthrough 2026, recognizing evidence from 84,145 asymptomatic individuals across 6 Asian countries. Dr. Dang Nguyen also received
ASCO 2026 RECAP | GENE SOLUTIONS PRESENT TWO CLINICAL STUDIES ADVANCING ctDNA APPLICATIONS IN CANCER CARE
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, Gene Solutions, in collaboration with the Medical Genetics Institute (MGI), proudly presented two landmark scientific abstracts.
Best of K‑CONNECT Summit 2026: Translating Multi-omics and AI Into Real-World Precision Oncology
At the K-CONNECT Summit 2026 in Da Nang, more than 250 international experts attended onsite, while over 1,000 participants joined online to explore how multi-omics, liquid biopsy, and Artificial Intelligence
Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test SINGAPORE, 28 May 2026 — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
TAIPEI, May 22, 2026 — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking
Single-Gene Disorders. Lifelong Impact. Early Screening Matters.
8 May marks World Thalassemia Day — a global moment to honor families living with thalassemia and raise awareness of inherited blood disorders. In 2026, the global campaign theme, “Hidden No More:
K-CONNECT SUMMIT 2026: Advancing AI, Multi-Omics, and Precision Oncology Across Asia-Pacific
K-CONNECT SUMMIT 2026, co-hosted by Gene Solutions, the Vietnam Institute of Clinical Medicine and Pharmacy, and the Vietnam Medical Association, will convene oncologists, healthcare professionals, researchers, and international experts to advance scientific exchange in early
Gene Solutions Introduces Dual Tumor-Blood Liquid Biopsy Comprehensive Profiling Upgrades for K-TRACK and K-4CARE
Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios,
CAP-Accredited Laboratory
Within our global network of 14 NGS laboratories, Gene Solutions maintains two facilities with CAP accreditation. This specialization in next-generation sequencing (NGS) demonstrates our commitment to international laboratory benchmarks.
Our adherence to these rigorous standards supports the delivery of reliable genomic testing for patients.
Gene Solutions Laboratories CAP#9709518
